Investigating the effect of theranostic approach with radiopharmaceuticals technetium 99m prostate membrane specific antigen - Lutchem 177 prostate membrane specific antigen in patients with glioblastoma

Start Date21 Nov 2024

Sponsor / Collaborator

Shiraz University of Medical Sciences

[+1]

NCT06024213

/ CompletedNot Applicable

French, Prospective, Post-marketing Study to Describe the Use, Detection Performance and Safety Profile of Infracyanine® (Indocyanine Green) for Breast Cancer Patients Undergoing a Sentinel Lymph Node (SLN) Biopsy.

This prospective, observational study will evaluate the patient-based sentinel lymph node detection rate when using the Infracyanine® (indocyanine green) dye technique in patients undergoing surgery for breast cancer.
The study will describe the demographic, clinical, and tumour characteristics of patients with breast cancer undergoing surgery.
The study will describe the characteristics of how the indocyanine green dye technique is used including the dose and volume of dye used, the number and type of injection sites used to give the dye, the equipment used to detect the dye and locate the sentinel lymph node, and whether indocyanine green is used on its own or with other dyes (blue dye and/or 99mTechnetium dye).
The study will evaluate the characteristics of sentinel lymph node biopsy procedures performed using indocyanine green dye including the number of biopsies performed, the time taken to detect the sentinel lymph node and perform the biopsy, and how many sentinel lymph nodes are detected using indocyanine green dye, blue dye, and 99mTechnetium dye.
The study will also assess the safety of using indocyanine green dye for 6 weeks following surgery.

Start Date06 Jun 2023

Sponsor / Collaborator

BTG International, Inc.

NCT05859971

/ CompletedEarly Phase 1

Use of ICG-fluorescent Imaging for Sentinel Lymph Node Mapping in Patients With Breast Cancer

The purpose of this research study is to assess the feasibility of using a different dye and imaging device, indocyanine green (ICG)-fluorescent imaging through the Asimov Imaging Platform, to perform sentinel lymph node biopsy.
Participants in this research study will be undergoing a sentinel lymph node biopsy as part of surgical treatment for breast cancer. Active participation will last through the post-operative visit.

Start Date13 Apr 2023

Sponsor / Collaborator

University of Wisconsin Madison

[+2]

100 Clinical Results associated with Technetium Tc-99m

100 Translational Medicine associated with Technetium Tc-99m

100 Patents (Medical) associated with Technetium Tc-99m

1,599

Literatures (Medical) associated with Technetium Tc-99m

01 Feb 2025·Data in Brief

Bone scan images dataset for study of bone metastases in adult breast cancer patients at IICS-UNA, Paraguay

Article

Author: Grossling-Vallejos, Benicio ; Villegas-Colmán, Carolina Elizabeth ; Barreto, Nicole ; Estigarribia, Pastor Pérez ; Mello-Román, Julio César ; Arnal, Marina ; Legal-Ayala, Horacio ; Rojas, Teresa ; Pedrozo, María Gloria ; Vázquez Noguera, José Luis ; Rivas, Ronald ; Giménez, Graciela ; Duarte, Cynthia ; Uldera, Andrés

This article presents 582 bone scan images from 291 adult patients who attended the Nuclear Medicine Service at the Instituto de Investigaciones en Ciencias de la Salud (IICS) of the Universidad Nacional de Asunción (UNA), Paraguay, between 2020 and 2024. The images were acquired using trimodal SPECT-CT-PET equipment, model AnyScan SCP, and the MEDISO brand. Approximately 20 mCi of technetium-99m methylene diphosphonate (^99mTc-MDP) was administered to each patient, producing whole-body planar images in anterior and posterior projections of the axial and appendicular skeleton with a resolution of 256 × 1024 pixels. The images were labeled according to the final diagnosis by a nuclear physician, covering conditions ranging from joint lesions to bone metastases. This dataset will be helpful for researchers working on bone scan image analysis using artificial intelligence techniques to classify bone metastases.

01 Feb 2025·Bioorganic & Medicinal Chemistry

Tc-99m labeled PSMA-617 as a potential SPECT radiotracer for prostate cancer diagnostics: Complexation optimization and its in vitro/vivo evaluation

Article

Author: Tippayamontri, Thititip ; Tachatumvitoon, Kalapaphuk ; Khomein, Piyachai ; Preuksarattanawut, Charasphat

Technetium-99m (Tc-99m) is the most employed radionuclide in nuclear imaging diagnostics worldwide for many diseases. The ideal physiochemical properties of Tc-99m (such as half-life and pure gamma energy) make it favorable for Single Photon Emission Computed Tomography (SPECT). In this study, we aim to expand the utilization of Tc-99m radiopharmaceutical toward prostate cancer diagnostics which is currently no FDA approved products and has been intensively examined for a potential candidate. The new formulation for Tc-99m complexation with PSMA-617, a current ligand for radionuclide therapy of prostate cancer with lutetium-177 (Lu-177), has been investigated. Co-complexation with citrate was utilized to improve the labeling efficiency by over 97 %. The stability of the new radiopharmaceutical was in vitro evaluated confirming that the Tc-99m labeled PSMA-617 remained stable for over a single half-life of Tc-99m in normal saline solution and in human serum. The in vivo study in the LNCaP xenografted mouse model confirmed a high selectivity of the new tracer toward prostate cancer.

01 Jan 2025·European Journal of Surgical Oncology

Development of an optimized MRI protocol for a rapid preoperative identification of sentinel lymph nodes using superparamagnetic iron oxide – The Gothenburg fast acquisition sentinel lymph node tracking magnetic resonance imaging protocol (GO-FAST-MRI)

Article

Author: de Coursey, Erica ; Leonhardt, Henrik ; Wärnberg, Fredrik ; Olofsson Bagge, Roger ; Zaar, Pontus ; Jalnefjord, Oscar ; Johansson, Iva ; Mirzaei, Nushin

INTRODUCTIONDetermining sentinel lymph node (SLN) status is important for treatment decisions in patients with melanoma. Superparamagnetic iron oxide nanoparticles (SPIO) combined with MRI have emerged as an alternative to Technetium^99m lymphoscintigraphy for preoperative mapping of SLN, however, the MRI protocols so far are extensive with long in-camera time. This study aimed to evaluate an optimized MRI protocol for rapid identification of SLNs using SPIO as a tracer, without compromising diagnostic quality, the GOthenburg Fast Acquisition Sentinel lymph node Tracking MRI (GO-FAST-MRI).MATERIALS AND METHODSIn this prospective single-center pilot study, patients with confirmed melanoma on the trunk or limbs, without clinically suspected lymph node metastasis, were eligible. All patients received an injection of 0.1 mL SPIO divided into four quadrants around the scar. The GO-FAST-MRI protocol, using only T1-weighted and Dixon sequences over the axillary or inguinal basins, was conducted no earlier than 30 min post-injection. Technetium and lymphoscintigraphy were used according to routine. SLN-biopsy was performed using a handheld magnetometer and gamma probe for SLN-detection.RESULTSTwenty-one patients were enrolled, and SLNs were successfully identified in all with both methods. The GO-FAST-MRI protocol was performed in 4 min and detected more SLNs than lymphoscintigraphy (54 vs 42), but the number of SLNs identified during surgery with the magnetometer and gamma probe was the same (50 for both methods). Of the SLNs removed, five were found to have metastases, all of which showed uptake of SPIO and Tc99m.CONCLUSIONThe novel GO-FAST-MRI protocol, with a 4-min scan-time, was feasible in detecting SLNs in all patients. Both the preoperative SLN-mapping and intraoperative SLN-detection using the magnetic technique was comparable to the radioactive technique.

News (Medical) associated with Technetium Tc-99m

30 Dec 2024

·www.prnewswire.com

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

MELBOURNE, Australia and BRUSSELS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports. Continue Reading Oncidium foundation logo NOBLE logo The NOBLE (Nobody Left Behind) Registry (NOBLE) is a global real-world evidence (RWE) study that aims to improve equity of access to state-of-the-art prostate cancer imaging. NOBLE is a collaboration combining the oncology and prostate cancer expertise of the Oncidium foundation as registry sponsor, Telix's intellectual property, and partnered clinical and operational support. An international network of sites support the registry locally through Principal Investigators (PIs), who are responsible for initiating and conducting research. Investigators collect patient data that will inform the development of TLX599-CDx, an investigational prostate cancer imaging agent that targets PSMA[1] using 99m-technetium (99mTc)-based SPECT[2] imaging. SPECT cameras are being clinically evaluated in this application because they are more widely available than the PET/CT[3] scanners used for gallium- or fluorine-based PSMA imaging, where access can be limited by socio-economic or geographic factors, as well as healthcare funding models. For every PET scanner available globally, there are four SPECT machines[4], making them a more accessible option when used with 99mTc – a radionuclide with a well-established supply chain, which can be produced in a bench-top generator. In the publication, the investigators report initial results based on a study of 40 patients in six countries[5], who received TLX599-CDx followed by planar and SPECT imaging. Investigators reported a change in management for 17 patients (42.5%) due to the use of SPECT-based PSMA imaging. No adverse events were reported. The authors conclude that technetium-based imaging "is a promising option to identify PSMA-positive prostate cancer on SPECT and could improve patient access to PSMA imaging worldwide", fulfilling an unmet need for millions of patients with prostate cancer who do not have straightforward access to PET imaging. Pete Tually, lead author, Director, TeleMed Remote Nuclear Medicine, and Principal Investigator for the Australian arm of NOBLE said, "The NOBLE Registry is an important initiative for increasing access to medicine globally, particularly for men in regional and remote locations. The interim results reported in our manuscript are promising, and we believe they provide a compelling basis for the further clinical study of technetium-99m-based PSMA imaging of prostate cancer." Rebecca Lo bue, CEO, Oncidium foundation, added, "PSMA-PET[6] imaging is today widely used in many countries worldwide, helping to extend life and improve treatment outcomes for men with prostate cancer through earlier diagnosis and better disease management. However, millions of men do not have access to this technology. These results from NOBLE represent an exciting milestone in bringing to market a powerful, cost-effective, and widely available alternative imaging tool that uses PSMA-SPECT technology." Dr. David N. Cade, Group Chief Medical Officer, Telix, continued, "Telix is proud to support the NOBLE Registry, which aims to improve access for patients who face geographic or economic barriers to state-of-the-art prostate cancer imaging. This publication by Pete Tually and his co-authors[7] signals a positive future for technetium-99m-based PSMA imaging, and we are excited to be part of this innovative program. As established leaders in PSMA imaging, Telix is committed to exploring multiple avenues to help men with prostate cancer get the diagnoses and treatments they need. We would like to thank all NOBLE investigators and the patients who have contributed towards this study." The EJNMMI Reports publication is available online at: Telix and the Oncidium foundation are planning follow-on clinical activity for NOBLE. This may include collaboration with Rhine Pharma on expanded access or compassionate use programs, exploring the use of technetium-99m and rhenium-188 as a theranostic pair for prostate cancer. This initiative reflects Telix's global commitment to access to medicine. About the Oncidium foundation The Oncidium foundation is a nonprofit organisation dedicated to advancing global access to radioligand therapy for cancer care. The foundation's priorities include raising awareness about radiotheranostics among patients and physicians, supporting and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients, globally. For more information visit About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[8], by the Australian Therapeutic Goods Administration (TGA)[9], and by Health Canada[10]. No other Telix product has received a marketing authorisation in any jurisdiction. Visit for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Logo - Logo - Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalClinical Result

25 Oct 2024

·endpts.com

Telix's new radiopharma spinout banks on one trial for success, CEO says

The future of Telix Pharmaceuticals’ new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO Christian Behrenbruch told Endpoints News in an interview . If Rhine’s only radiotherapy asset, dubbed RHN001, passes a Phase 1/2 trial, Telix will look for external investors to back the spinout into its next stages, Behrenbruch said. Otherwise, the asset will likely be handed back to Heidelberg University Hospital, where it was developed, he added. Telix announced the spinoff on Tuesday. Rhine is currently a wholly-owned subsidiary of Telix, but it will become independent once “key milestones are achieved,” though the release did not elaborate further. Rhine is yet to finalize employee numbers as it is still being formed, a spokesperson said. As Australian radiopharma Telix is growing, RHN001 no longer fits with its “core pipeline,” so the company, alongside Heidelberg University Hospital, decided to spin off the asset’s development with the new entity, Behrenbruch said. Telix will fund the early-phase trial, and results are expected in a year. RHN001 is being investigated for prostate cancer. When it has the radioisotope technetium-99m, it can be used for imaging. And if it has rhenium-188, it could have potential as a radiotherapy. The radiopharma space is heating up, and Telix has been busy bolstering its portfolio through numerous acquisitions, notably buying up RLS Radiopharmacies to expand its presence in the US. Manufacturing has been a talking point in the radiopharma space, with companies like Novartis needing to fix supply issues for its assets. RHN001’s two isotopes can be manufactured inside generators at any location, which require less manufacturing infrastructure compared to bioreactors that make more traditional isotopes like lutetium-177 and actinium-225, Behrenbruch said. Behrenbruch compared the generators to fridges where the isotopes are like ice cubes. This is a more decentralized manufacturing approach, which avoids the transportation of isotopes that have short shelf lives, making them difficult to ship , Behrenbruch said. Telix and Heidelberg University Hospital began their partnership back in 2021 to research radiotherapies for cancer affecting urinary tracts and reproductive parts.

Acquisition

11 Apr 2024

·www.biospace.com

Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.

BURNABY, British Columbia--(BUSINESS WIRE)-- ARTMS Products Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes. ARTMS will support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes for Telix’s portfolio of products, such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients. In addition, ARTMS’ portfolio of advanced cyclotron technologies has immediate application and differentiation for Telix in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At). The history of ARTMS is rooted in a Canadian government funded project focused on solid target production of 99mTc. After that project was successfully completed, the innovation continued and resulted in a full suite of PET products. In 2017, ARTMS Inc. was formed with support and seed funding from Quark Venture, through their Global Health Sciences Fund (GHS) and founding institutions TRIUMF, BC Cancer, Lawson Health Research Institute and the Center for Probe Development. In May of 2020, ARTMS completed a $20M USD Series A fundraising that included GHS and welcomed Deerfield Management to the ARTMS family. In the subsequent years ARTMS has played a critical role in alternative production of medical isotopes with a focus on accelerating the production capabilities of the world’s most commonly installed cyclotrons. The collaboration between ARTMS’ unparalleled team, its investors and founding members has resulted in a truly differentiated organization. Solomon Partners Securities LLC acted as financial advisor and Norton Rose Fulbright Canada LLP acted as legal advisor to ARTMS during the negotiations and due diligence process related to the acquisition by Telix. About ARTMS, Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry. For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter/X @ARTMS_Inc/X and LinkedIn and visit About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Acquisition

100 Deals associated with Technetium Tc-99m

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14227

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Embolism	US	Cyclomedica Australia Pty Ltd.	29 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


307 Hall Y10-Y12 (EANM2024)	Not Applicable	Squamous cell carcinoma of the oral cavity	65	Technetium-labeled nanocolloidal albumin (Sentinel lymph node biopsy with 99mTc-Nanocoll)	olewqqaxtt(eimtcdakmo) = pavkiwngnn cygswuvzji (jigjeztagr ) View more	Positive	27 Sep 2024
NCT05859971 (CTgov)	Early Phase 1	Breast Cancer	10	SLN mapping+isosulfan blue+technetium-99m	awfomavtkt(aqeczcgldr) = ipuljoqqlf wezeqnkjbo (ansmwhowvu, uvmizzgxno - ssjdkudjnu) View more	-	15 Aug 2024
NCT01982123 (CTgov)	Not Applicable	Lung Cancer	12	SPECT/CT+Technetium Tc-99m DTPA	wkixswdzuq(xxqvlxeypn) = cdrjtvnklc nbbnyftbzk (jqjckyfvdn, wymamoowej - rczmzeaghj) View more	-	13 Dec 2018
EANM2018	Not Applicable	Tc-99m pertechnetate	50	Technetium (Tc-99m pertechnetate thyroid scintigraphy)	svynkcbmnf(hxcfpddpfv) = leydzhgnac adktchtdiy (ugiuusovvj )	-	18 Sep 2018
NCT02279108 (FLUOTECH, CTgov)	Phase 3	Breast Cancer	99	indocyanine green+isotope (Double Detection Indocyanine + Isotope)	tviubztmtv(pjlwsusdhl) = byxiobveys eocphiggdq (zxiaasozhz, ttjfujvklc - gtvajccnfd) View more	-	09 Apr 2018
NCT02279108 (FLUOTECH, CTgov)	Phase 3	Breast Cancer	99	isotope (Isotope Detection Alone)	tviubztmtv(pjlwsusdhl) = ozkznrrzaj eocphiggdq (zxiaasozhz, wdsiihjsnu - hjomazelrr) View more	-	09 Apr 2018
EANM2017	Not Applicable	Breast Cancer	11	Technetium-99m (99mTc-1-thio-D-glucose)	(tstownclbj) = vcxpgunutl propoppauv (htfaclmgtn ) View more	Positive	11 Sep 2017
EANM2016	Not Applicable	-	-	tech-netium-99m (Generator of technetium-99m based on activation molybdenum-99)	axmswdzdzt(lqzjwyuzrq) = trvovhzqzb yghhutzern (wrumkdfgsh ) View more	-	21 Sep 2016
EANM2016	Not Applicable	-	-	Technetium (Cobalt (60-Co))	assffxghev(jgdsripdzp) = when dosimeters are attached and unattached to the vial for the 99m- Tc measures an output coupling is observed iayiewlsya (xyxqgqbnwv )	-	21 Sep 2016
ASTRO2010	Not Applicable	Localized Prostate Carcinoma Neoadjuvant	-	Isotope (I-125)	ccmrroyxci(swvpfqlqfc) = A trend toward more acute urinary retention was seen with HDR 2% vs. 7% txuviccwde (lreeeqldhb )	Positive	01 Nov 2010
ASTRO2010	Not Applicable	Localized Prostate Carcinoma Neoadjuvant	-	Pd-103		Positive	01 Nov 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis